AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 06:58:05 2026-01-23 am EST			5-day change	1st Jan Change
13,639.00 ^GBX	+0.58%		-2.92%	-1.08%

04:53am	Storebrand Europa Rose by 1.84 Percent in December – Increased Global Uncertainty	FW
Jan. 22	HSBC chair to join PM Starmer on China visit next week - Sky	AN

Deutsche Bank Research cuts Eurowag to 'hold'

Published on 09/17/2025 at 04:48 am EDT

Alliance News

+0.58%

+0.93%

+0.86%

-0.07%

+0.83%

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

----------

FTSE 100

----------

JPMorgan raises Fresnillo price target to 2,500 (2,100) pence - 'overweight'

----------

LBBW cuts Rio Tinto price target to 5,300 (5,600) pence - 'buy'

----------

Jefferies cuts Sage Group price target to 1,320 (1,480) pence - 'buy'

----------

Goldman Sachs raises AstraZeneca price target to 15,013 (14,883) pence - 'buy'

----------

FTSE 250

----------

Deutsche Bank Research cuts Eurowag to 'hold' (buy) - price target 110 (90) pence

----------

Deutsche Bank raises Trustpilot price target to 343 (331) pence - 'buy'

----------

Citigroup cuts B&M price target to 456 (485) pence - 'buy'

----------

SMALL CAP

----------

RBC raises MJ Gleeson price target to 400 (375) pence - 'underperform'

----------

Berenberg raises Galliford Try price target to 530 (510) pence - 'buy'

----------

Deutsche Bank Research cuts SThree price target to 290 (360) pence - 'buy'

----------

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
ASTRAZENECA PLC	13,639.00GBX	+0.58%	-2.92%	284B
RIO TINTO PLC	6,546.00GBX	+0.93%	+3.05%	148B
FRESNILLO PLC	4,119.00GBX	+0.86%	+9.82%	40.61B
SAGE GROUP PLC	1,021.75GBX	-0.07%	-3.13%	13B
TRUSTPILOT GROUP PLC	218.60GBX	+0.83%	-6.03%	1.19B

Latest news about AstraZeneca PLC

04:53am	Storebrand Europa Rose by 1.84 Percent in December – Increased Global Uncertainty	FW
Jan. 22	HSBC chair to join PM Starmer on China visit next week - Sky	AN
Jan. 22	Daiichi and AstraZeneca's Enhertu wins sixth approval in China	AN
Jan. 21	National Medical Products Administration Approves Enhertu in China as the First and Only Her2 Directed Dc for the Second-Line Treatment of Patients with Her2 Positive Metastatic Gastric Cancer	CI
Jan. 21	Stocks rally as Trump calms Greenland rhetoric	AN
Jan. 21	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
Jan. 21	UK-China business forum to be revived during expected PM Starmer trip	AN
Jan. 21	Britain, China to revive 'Golden Era' business dialogue during Starmer visit, sources say	RE
Jan. 21	Britain's AstraZeneca, BP, HSBC, IHG, JLR, Rolls Royce, Schroders, Stanchart expected to join - sources	RE
Jan. 21	Britain's Astrazeneca, BP, HSBC, IHG, JLR, Rolls Royce, Schroders, Stanchart expected to join - sources	RE
Jan. 20	European Stocks Close Lower in Tuesday Trading; UK Unemployment Rises to 5.1%	MT
Jan. 20	Global drugmakers rush to boost US presence as tariff threat looms	RE
Jan. 20	European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	MT
Jan. 20	Sector Update: Health Care Stocks Decline Premarket Tuesday	MT
Jan. 20	Sector Update: Health Care	MT
Jan. 20	Stocks sink as Greenland tensions hit sentiment	AN
Jan. 20	London's FTSE 100 slips as Trump's tariff threats over Greenland loom	RE
Jan. 20	AstraZeneca to complete direct listing in NY on February 2	AN
Jan. 20	AstraZeneca, Daiichi Sankyo Say European Medicines Agency Validates Enhertu Application for Breast Cancer	MT
Jan. 20	AstraZeneca to Delist ADSs, Debt Securities From Nasdaq	MT
Jan. 20	Euro-American Tensions Continue to Weigh on Stock Markets
Jan. 20	Stockholm Bullets - Rottneros Plummets on a Red Exchange	FW
Jan. 20	AstraZeneca to Shift US Listing to New York Stock Exchange from Nasdaq	MT
Jan. 20	AstraZeneca to complete direct listing on NYSE	RE
Jan. 20	AstraZeneca to delist from Nasdaq, join NYSE in February	RE

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (5.8%). Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).

Employees

94,300

Sector

Pharmaceuticals

Calendar

Feb. 10 - Q4 2025 Earnings Release

More about the company